What happened (Rajya Sabha data on Jan Aushadhi Kendras and sales under PMBJP)
The Ministry of Chemicals and Fertilizers, Department of Pharmaceuticals, reported implementation and sales figures for the Pradhan Mantri Bhartiya Janaushadhi Pariyojna (PMBJP) in a Rajya Sabha written reply by Minister of State for Chemicals and Fertilizers Smt. Anupriya Patel.
Key reported points are:
20,149 Jan Aushadhi Kendras (JAKs) were opened across India as on 30.06.2026.The PMBJP product basket includes 2,110 medicines and 315 surgicals, medical consumables and devices, covering major therapeutic groups such as cardiovascular, anti-cancer, anti-diabetic, anti-infectives, anti-allergic, and gastro-intestinal medicines, and nutraceuticals.Government stated that medicines sold under PMBJP are available at rates about 50% to 80% cheaper than branded medicines.For financial year 2025-26, sales of medicines with MRP worth ₹2,252.19 crore were made under the scheme.For financial year 2026-27, sales of medicines with MRP worth ₹474.40 crore were made up to 30.06.2026.
Background and earlier position (what PMBJP is trying to do)
PMBJP aims to improve access to affordable generic medicines through retail availability. Jan Aushadhi Kendras (JAKs) act as the physical front-end where beneficiaries can buy medicines at discounted rates compared with branded alternatives.
Related current affairs
- PMBJP: 20,149 Jan Aushadhi Kendras operational; medicines up to 50–80% cheaper and quality ensured
- Operation and performance of PMBJP (Jan Aushadhi Kendras)
- Jan Aushadhi Kendras (JAKs) performance and expansion under PMBJP scheme
- District-wise number of Jan Aushadhi Kendras in Assam (as on 30.06.2026)
- Schemes to strengthen pharmaceutical and bulk drug manufacturing in Maharashtra
- Parliamentary panel flags under-utilisation of allocations in Department of Pharmaceuticals schemes and highlights corrective measures